news
Global subcutaneous drug delivery devices market expected to grow
A new report has predicted that the global subcutaneous drug delivery devices market will grow to $17,290.47 million in 2027 from $9,243.80 million in 2018.
List view / Grid view
Therapeutics
news
NHS England and Vertex announce agreement for cystic fibrosis medicines
A new agreement will allow eligible cystic fibrosis patients in England to have access to CFTR modulators to treat the underlying cause of their disease.
news
New breakthrough can effectively deliver medications into the brain
Scientists have found a way to effectively transport medication into the brain which could lead to improved treatments for neurological and neurodegenerative diseases.
news
Treatment to increase pain-free light exposure approved
The FDA has approved the first treatment to increase pain-free light exposure in patients with the rare disorder, erythropoietic protoporphyria.
news
First treatment for children with rare vasculitis diseases approved
Rituxan (rituximab) is the first approved treatment for children with rare vasculitis diseases, in which a patient’s small blood vessels become inflamed.
news
Daratumumab approved for multiple myeloma treatment
The drug daratumumab has been approved for treatment of multiple myeloma, demonstrating increased efficacy when used in combination with other drugs.
whitepaper
Scientific poster: Common Laboratory Techniques in the Drug Discovery Workflow
The characterization of novel therapeutics involves many chemical processes.
article
Can calorimetry provide accurate estimates of long‑term stability for monoclonal antibodies?
Differential scanning calorimetry (DSC) has been one of the most widely used techniques to characterise the temperature stability of monoclonal antibodies (mAbs) and provide important information in formulation optimisation. However, despite its widespread use, not all the information contained in DSC data, especially denaturation kinetics, is routinely extracted. In this…
article
Single-use strategies for downstream processing
All therapeutic developers and manufacturers are under intense pressure to improve efficiency and productivity and reduce costs, all while maintaining the highest quality standards.
whitepaper
Application note: Cell-Based Therapies – Be on the Safe Side
Get QC Results for Advanced Therapy Medicinal Products (ATMPs) Before Treatment.
news
British Columbia first province to switch patients to biosimilars
British Columbia has said it will switch as many as 20,400 patients from three branded biologic drugs to cheap biosimilars.
news
Drug combination may become new standard treatment for advanced kidney cancer
Immunotherapy drug plus targeted agent provided better progression-free survival and shrank tumors in more patients than standard one-drug treatment...
news
Pricing dispute over cystic fibrosis drug Orkambi continues in the UK
Campaigners call for UK Government to intervene on pricing dispute over cystic fibrosis drug Orkambi...
news
Developing the production of the radioisotope Tc-99m within the US
A team of university researchers have collaborated together to develop a method to produce the radioisotope Tc-99m in the US to prevent having to import it...
whitepaper
Application Note: Quantitation of intact therapeutic protein in plasma matrix by LC/MS
A complete workflow to quantify intact therapeutic proteins in plasma matrix has been developed, covering three critical components in preclinical sample analysis: target protein enrichment/purification, LC/MS data acquisition and quantitative data analysis.
